IRulya Therapeutics Inc.
IRLA· Nasdaq
IRLAIRulya Therapeutics Inc.
Filed Oct 29, 2021 · 10-Q · 29 days after period end · 0000950170-21-002495
| Metric | Q3 2021 | Q3 2020 | Q3 2019 | Q3 2018 |
|---|---|---|---|---|
| Net Income | -$21.71M | -$21.51M | -$9.86M | -$2.52M |
| EPS Diluted | -$0.73 | -$0.73 | -$0.37 | -$0.75 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
IRulya Therapeutics Inc. · CIK 1662774 · Engraved from SEC EDGAR
ended Sep 30, 2021 · filed Oct 29, 2021 · 29 d after period end
